Kathy Boxall

2.5k total citations
20 papers, 821 citations indexed

About

Kathy Boxall is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Kathy Boxall has authored 20 papers receiving a total of 821 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 9 papers in Oncology and 6 papers in Cell Biology. Recurrent topics in Kathy Boxall's work include Cancer-related Molecular Pathways (6 papers), Microtubule and mitosis dynamics (6 papers) and DNA Repair Mechanisms (5 papers). Kathy Boxall is often cited by papers focused on Cancer-related Molecular Pathways (6 papers), Microtubule and mitosis dynamics (6 papers) and DNA Repair Mechanisms (5 papers). Kathy Boxall collaborates with scholars based in United Kingdom, United States and Australia. Kathy Boxall's co-authors include G. Wynne Aherne, Ian Collins, Paul Workman, Swee Y. Sharp, Michelle D. Garrett, Swen Hoelder, Richard Bayliss, Florence I. Raynaud, Corine Mas-Droux and John Reader and has published in prestigious journals such as PLoS ONE, Cancer Research and Clinical Cancer Research.

In The Last Decade

Kathy Boxall

20 papers receiving 812 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kathy Boxall United Kingdom	15	660	203	172	162	157	20	821
Jason Cellitti United States	16	640 1.0×	129 0.6×	120 0.7×	154 1.0×	62 0.4×	21	785
Rob Howes United Kingdom	13	578 0.9×	118 0.6×	154 0.9×	420 2.6×	116 0.7×	14	1.1k
Jörg Bomke Germany	13	572 0.9×	94 0.5×	108 0.6×	104 0.6×	97 0.6×	15	816
Matthew J. Fitzgibbon United States	10	951 1.4×	212 1.0×	180 1.0×	160 1.0×	83 0.5×	11	1.1k
Andrew R. Bayly United Kingdom	4	694 1.1×	129 0.6×	132 0.8×	239 1.5×	54 0.3×	4	945
Pathik S. Brahmkshatriya India	13	326 0.5×	157 0.8×	132 0.8×	449 2.8×	152 1.0×	28	844
Rachel McMenamin United Kingdom	6	400 0.6×	146 0.7×	248 1.4×	91 0.6×	62 0.4×	8	600
Thomas P. Matthews United Kingdom	12	400 0.6×	113 0.6×	128 0.7×	163 1.0×	58 0.4×	21	561
Alexander Gozman United States	8	612 0.9×	120 0.6×	139 0.8×	61 0.4×	103 0.7×	22	778
Brinton Seashore‐Ludlow Sweden	20	649 1.0×	186 0.9×	133 0.8×	298 1.8×	67 0.4×	51	1.1k

Countries citing papers authored by Kathy Boxall

Since Specialization

Citations

This map shows the geographic impact of Kathy Boxall's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathy Boxall with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathy Boxall more than expected).

Fields of papers citing papers by Kathy Boxall

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathy Boxall. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathy Boxall. The network helps show where Kathy Boxall may publish in the future.

Co-authorship network of co-authors of Kathy Boxall

This figure shows the co-authorship network connecting the top 25 collaborators of Kathy Boxall. A scholar is included among the top collaborators of Kathy Boxall based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathy Boxall. Kathy Boxall is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Matheson, Christopher J., Christopher R. Coxon, Richard Bayliss, et al.. (2020). 2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase. RSC Medicinal Chemistry. 11(6). 707–731. 14 indexed citations

Coxon, Christopher R., Christopher Wong, Richard Bayliss, et al.. (2016). Structure-guided design of purine-based probes for selective Nek2 inhibition. Oncotarget. 8(12). 19089–19124. 12 indexed citations

Gurden, Mark D., Isaac M. Westwood, Amir Faisal, et al.. (2015). Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance. Cancer Research. 75(16). 3340–3354. 24 indexed citations

Westwood, Isaac M., Kathy Boxall, Nathan Brown, et al.. (2013). Fragment-Based Screening Maps Inhibitor Interactions in the ATP-Binding Site of Checkpoint Kinase 2. PLoS ONE. 8(6). e65689–e65689. 12 indexed citations

Couty, S., Isaac M. Westwood, Andrew Kalusa, et al.. (2013). The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design. Oncotarget. 4(10). 1647–1661. 17 indexed citations

Walton, Mike I., Paul D. Eve, Angela Hayes, et al.. (2012). CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs. Clinical Cancer Research. 18(20). 5650–5661. 69 indexed citations

Innocenti, Paolo, Kwai-Ming J. Cheung, Corine Mas-Droux, et al.. (2012). Design of Potent and Selective Hybrid Inhibitors of the Mitotic Kinase Nek2: Structure–Activity Relationship, Structural Biology, and Cellular Activity. Journal of Medicinal Chemistry. 55(7). 3228–3241. 56 indexed citations

Lainchbury, Michael, Thomas P. Matthews, Tatiana McHardy, et al.. (2012). Discovery of 3-Alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as Selective, Orally Bioavailable CHK1 Inhibitors. Journal of Medicinal Chemistry. 55(22). 10229–10240. 22 indexed citations

Innocenti, Paolo, Corine Mas-Droux, Kathy Boxall, et al.. (2011). Benzimidazole Inhibitors Induce a DFG-Out Conformation of Never in Mitosis Gene A-Related Kinase 2 (Nek2) without Binding to the Back Pocket and Reveal a Nonlinear Structure−Activity Relationship. Journal of Medicinal Chemistry. 54(6). 1626–1639. 43 indexed citations

10.

Walton, Michael I., Paul D. Eve, Angela Hayes, et al.. (2010). The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106. Molecular Cancer Therapeutics. 9(1). 89–100. 63 indexed citations

11.

Matthews, Thomas P., Tatiana McHardy, Kathy Boxall, et al.. (2010). Design and evaluation of 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines as inhibitors of checkpoint and other kinases. Bioorganic & Medicinal Chemistry Letters. 20(14). 4045–4049. 20 indexed citations

12.

Caldwell, John, E. Jane Welsh, Victoria E. Anderson, et al.. (2010). Structure-Based Design of Potent and Selective 2-(Quinazolin-2-yl)phenol Inhibitors of Checkpoint Kinase 2. Journal of Medicinal Chemistry. 54(2). 580–590. 42 indexed citations

13.

Whelligan, Daniel K., Dawn Taylor, Douglas W. Thomson, et al.. (2010). Aminopyrazine Inhibitors Binding to an Unusual Inactive Conformation of the Mitotic Kinase Nek2: SAR and Structural Characterization. Journal of Medicinal Chemistry. 53(21). 7682–7698. 56 indexed citations

14.

Matthews, Thomas P., Kathy Boxall, Martin Fisher, et al.. (2009). Identification of Inhibitors of Checkpoint Kinase 1 through Template Screening. Journal of Medicinal Chemistry. 52(15). 4810–4819. 35 indexed citations

15.

Hilton, Stephen T., Sébastien Naud, John Caldwell, et al.. (2009). Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2. Bioorganic & Medicinal Chemistry. 18(2). 707–718. 48 indexed citations

16.

McErlean, Christopher S. P., Christopher J. Davis, Swee Y. Sharp, et al.. (2007). Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin. Organic & Biomolecular Chemistry. 5(3). 531–531. 16 indexed citations

17.

Sharp, Swee Y., Kathy Boxall, Stephen Connelly, et al.. (2006). Inhibition of Hsp90 with Synthetic Macrolactones: Synthesis and Structural and Biological Evaluation of Ring and Conformational Analogs of Radicicol. Chemistry & Biology. 13(11). 1203–1215. 53 indexed citations

18.

Hardcastle, Anthea, Kathy Boxall, P J Tomlin, et al.. (2005). Solid-Phase Immunoassays in Mechanism-Based Drug Discovery: Their Application in the Development of Inhibitors of the Molecular Chaperone Heat-Shock Protein 90. Assay and Drug Development Technologies. 3(3). 273–285. 8 indexed citations

19.

Sharp, Swee Y., Alison Maloney, Paul A. Clarke, et al.. (2004). Mechanism of action of a novel series of inhibitors of the Hsp90 molecular chaperone. Cancer Research. 64. 922–923. 1 indexed citations

20.

Wright, Lisa, Xavier Barril, Brian Dymock, et al.. (2004). Structure-Activity Relationships in Purine-Based Inhibitor Binding to HSP90 Isoforms. Chemistry & Biology. 11(6). 775–785. 210 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact